Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
Christopher F BellPriyanka JainRaj DesaiDaniel C GibbonsMyriam DrysdaleMaral DerSarkissianVishal PatelHelen J BirchEmily J LloydAdina ZhangMei Sheng Duhnull nullPublished in: Clinical drug investigation (2024)
Sotrovimab demonstrated clinical effectiveness in preventing severe outcomes (hospitalisation, mortality) in the period 27 September 2021-30 April 2022, which included Delta and Omicron BA.1 variants and an early surge of Omicron BA.2 variant.
Keyphrases
- coronavirus disease
- sars cov
- randomized controlled trial
- systematic review
- quality improvement
- copy number
- cardiovascular events
- respiratory syndrome coronavirus
- early onset
- risk factors
- type diabetes
- cardiovascular disease
- gene expression
- insulin resistance
- genome wide
- adipose tissue
- skeletal muscle
- combination therapy